Back

Heparin and low-molecular-weight heparin switch associated with an increase in bleeding complications in patients on apixaban undergoing catheter ablation: The AMPER ABLATION study

18 March 2019 (08:30 - 18:00)
Organised by:
Congress Presentation Part of: Poster session 2 - Atrial Fibrillation - Treatment Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2019

About the speaker

Photo
Professor Jacques Mansourati

University Hospital of Brest, Brest (France)

61 More presentations in this session

Presentation thumbnail
Professor P. Gora (Bad Oeynhausen, DE)
Abstract Slides
Presentation thumbnail
Professor K. Neven (Essen, DE)
Abstract Slides
Presentation thumbnail
Professor N. Reinsch (Essen, DE)
Abstract Slides
Presentation thumbnail
Professor N. Reinsch (Essen, DE)
Abstract Slides
Presentation thumbnail
Professor N. Reinsch (Essen, DE)
Abstract Slides

Access the full session

Session thumbnail
Poster session 2 - Atrial Fibrillation - Treatment

The Event

Event poster

EHRA 2019

18 March 2019 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Safety and efficacy of anticoagulation therapy post atrial fibrillation ablation
9 March 2024
thumbnail
Congress Presentation
Comparative effectiveness and safety of apixaban and low-molecular weight heparin among patients with venous thromboembolism and active cancer in an extended treatment setting
28 August 2023
thumbnail
Congress Session
Stroke and bleeding risk in atrial fibrillation: walking the tight rope
25 August 2023
thumbnail
Congress Session
Arrhythmias during pregnancy: help and not harm
31 March 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources